(Q44503507)

3 December 2017

title

Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey (English)

1 reference

3 December 2017

0 references

ascending cholangitis

0 references

sclerosing cholangitis

1 reference

primary sclerosing cholangitis

inferred from title

1 reference

M Zuin

13

0 references

author name string

L Okolicsanyi

1

1 reference

3 December 2017

M Groppo

2

1 reference

3 December 2017

A Floreani

3

1 reference

3 December 2017

A M Morselli-Labate

4

1 reference

3 December 2017

A G Rusticali

5

1 reference

3 December 2017

A Battocchia

6

1 reference

3 December 2017

M Colombo

7

1 reference

3 December 2017

G Galatola

8

1 reference

3 December 2017

G Gasbarrini

9

1 reference

3 December 2017

M Podda

10

1 reference

3 December 2017

G Ricci

11

1 reference

3 December 2017

F Rosina

12

1 reference

3 December 2017

publication date

1 May 2003

1 reference

Digestive and Liver Disease

3 December 2017

published in

1 reference

3 December 2017

volume

35

1 reference

3 December 2017

issue

5

1 reference

3 December 2017

page(s)

325-331

1 reference

Colchicine treatment of primary sclerosing cholangitis

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Ursodeoxycholic acid for primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

A revised natural history model for primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Effect of different doses of ursodeoxycholic acid in chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Absorption of urso- and chenodeoxycholic acid and their taurine and glycine conjugates in rat jejunum, ileum, and colon.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Pathogenesis and medical therapy of primary sclerosing cholangitis. Any news?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Serum autoantibodies in patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

Management of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900076-8

7 January 2021

10.1016/S1590-8658(03)00076-8

Identifiers

DOI

1 reference

3 December 2017

1 reference